RB1 and neoplasm: Numerous CDK4/6 inhibitors potently suppress the proliferation of Foxp3 + regulatory T cells (TReg) in the tumor microenvironment (TME), which is likely an RB-dependent phenomenon [37, 62, 81, 82].